The medical device industry, with its bright performance, is still bullish in 2023

Wind data show that as of January 31, 233 A-share pharmaceutical companies have unveiled their 2022 performance forecasts, and more than half of the companies are expected to be positive, the performance of bright companies mainly from traditional Chinese medicine, medical devices and other bright.

Among them in the medical device industry, as of January 31, 2023, the number of medical device companies that released performance forecasts exceeded 30, and more than half of the performance forecasts.

From the point of view of net profit increase, Jiu'an Medical net profit increase in the top, the company is expected to achieve 16.5 billion yuan to 17.5 billion yuan of net profit attributable to the mother in 2022, an increase of 1715.90% to 1825.95%.

In addition, there are many medical device companies such as Ahuilong, Shanwai Mountain, Jardine Ka Ye, Late Reading Biology, Kepu Biology, etc., which are expected to increase their net profit by more than 100% in 2022. For example, Yahuilong expects to achieve a net profit attributable to owners of the parent company of 1.02 billion yuan to 1.1 billion yuan in 2022, an increase of 398.17% to 437.25% compared with the same period of the previous year. JASL expects to achieve a net profit attributable to the parent owner of RMB 351 million to RMB 407 million in 2022, an increase of 140.85% to 179.67% compared with the same period of the previous year; Shanwai Mountain expects a net profit attributable to the parent owner of the company to increase 117.68% to 226.5% in 2022, reaching RMB 42.39 million to RMB 63.58 million compared with the same period of the previous year.

For the reasons of the growth in performance, Jiu'an Medical said that, due to the impact of the epidemic, the company's demand for epidemic prevention products such as kits sold in the United States increased significantly, and the sales revenue of related products increased significantly. At the same time, with the increase in sales of kits and other products in the United States, it brought good brand awareness and user reputation, thus driving the sales of the company's other products. In the background of the bright performance, on the evening of January 31, Jiu'an Medical also released an announcement on the use of its own funds for entrusted financial management and securities investment. According to the announcement, the company intends to use the maximum amount of a total of 20 billion yuan for financial management investment.

AAHIL said that it is mainly due to the sales growth of both the company's non-New Crown self-produced product business and New Crown product business during the reporting period.

Jardine Matheson pointed out in its earnings forecast that it was mainly due to the continued impact of product recalls by its competitors, the further increase in demand for the company's products in the U.S. market and the growth in orders; and with the continued stabilization of the epidemic, the sales of conventional sales business continued to grow.

Shanwai Shan said that in 2022, the company adhere to independent research and technological innovation, to overcome the key core technology, continue to optimize production and operation, strengthen cost control, to achieve a steady improvement in operating results, business continues to improve. The company's performance improvement is mainly manifested in the sales of the company's core products hemodialysis machine and continuous blood purification equipment (CRRT) to maintain rapid growth, resulting in an increase in operating income.

Although the performance growth of many medical device companies is due to the increase in demand for nucleic acid testing business, many institutions are still bullish on the medical device track as the new medical infrastructure advances, and the medical device industry is driven by favorable policies, an aging population, and consumer upgrades, looking ahead to 2023.

For example, Hua An Securities believes that the medical technology sector contains opportunities. Innovative drug and innovative device companies are expected to see a revaluation in 2023. It is recommended to focus on companies whose products can solve clinical problems or have been commercialized and have a good market pattern.

Caixin Securities also issued a research report, long-term domestic medical demand growth trend does not change, in-hospital surgery volume is expected to usher in a rebound, out-of-hospital consumer medical will also continue to warm; the current round of medical infrastructure is in full swing in the country, production capacity will be released one after another, special construction, equipment procurement orders will gradually cash, at the same time, after the epidemic era, the global strengthening of public health construction, but also for domestic medical equipment products to provide the development of overseas At the same time, the post-epidemic era, the global strengthening of public health construction, also provides development opportunities for domestic medical equipment products to go abroad, medical equipment industry, domestic substitution, internationalization process continues to accelerate.